JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
JB062 (compound 6b; 40 μM; 24 h) inhibits cytokinesis in Cos-7 cells[1].
JB062 (COS-7 cells) has cytotoxic to human cancer cells but not normal cells with a CC10 value of 36 μM[1].
References:
[1]. Smith JD, et, al. Isoform selectivities of novel 4-hydroxycoumarin imines as inhibitors of myosin II. Eur J Med Chem. 2022 Dec 12;247:115008.